✦ LIBER ✦

Phase 0 clinical trials in oncology: a paradigm shift for early drug development?

✍ Scribed by Chris H. Takimoto

Publisher: Springer
Year: 2008
Tongue: English
Weight: 271 KB
Volume: 63
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-008-0789-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Guideline to regulations for radiopharma

Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU

✍ Alfons Verbruggen; Heinz H. Coenen; Jean-Robert Deverre; Denis Guilloteau; Bengt 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 160 KB

Alzheimer's disease, estrogens, and clin

Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders

✍ Neil Howell; James Dykens; Walter H. Moos 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB 👁 2 views

Differences between a drug regimen emplo

Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice : A note of caution

✍ Maurie Markman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

It is reasonable to assume that a decision to permit wider access to new anticancer agents after the completion of only phase 1 trials will almost certainly result in the administration of such therapy to a substantial population of individuals who would not have been eligible for such “registration

A call to restructure the drug developme

A call to restructure the drug development process: Government over-regulation and non-innovative late stage (Phase III) clinical trials are major obstacles to advances in health care

✍ Thomas C. Jones 📂 Article 📅 2005 🏛 Springer Netherlands 🌐 English ⚖ 187 KB

Efficacy and safety of mangafodipir tris

Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

✍ Michael Federle; Judith Chezmar; Daniel L. Rubin; Jeffrey Weinreb; Patrick Freen 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB

The combination of cisplatin, doxorubici

The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma: A phase II randomized trial of the Italian oncology group for clinical research

✍ Vincenzo De Lisi; Giorgio Cocconi; Francesco Angelini; Francesco Cavicchi; Franc 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 2 views

## BACKGROUND. In a randomized Phase I1 study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) comhination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) Combination, in pat